5-year Analysis of NeoSphere Trial of Pertuzumab Supports Primary Endpoint

Share this content:
A 5-year analysis of the NeoSphere trial supports the primary endpoint of pathological complete response.
A 5-year analysis of the NeoSphere trial supports the primary endpoint of pathological complete response.

A 5-year analysis of the NeoSphere trial supports the primary endpoint of pathological complete response and suggests that neoadjuvant pertuzumab is beneficial when added to trastuzumab and docetaxel, a report published in The Lancet Oncology has shown.1

The primary analysis of the phase 2 trial demonstrated that combining neoadjuvant pertuzumab with trastuzumab and docetaxel significantly improved pathological complete response. Now, researchers have reported updated analyses of the primary endpoint, as well as 5-year progression-free survival, disease-free survival, and safety.

For the multicenter, open-label study, researchers enrolled 417 treatment-naïve patients with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Participants were randomly assigned 1:1:1:1 to receive 4 neoadjuvant cycles of trastuzumab 6 mg/kg every 3 weeks (8 mg/kg loading dose) plus docetaxel 75 mg/m2 every 3 weeks (increasing to 100 mg/m2 from cycle 2 if tolerated; group A), pertuzumab 420 mg every 3 weeks (840 mg loading dose) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D).

Following surgery, patients received fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 (FEC) every 3 weeks for 3 cycles (group C received docetaxel for 4 cycles prior to FEC), and trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment.

Results showed that  5-year progression-free survival rates were 81% (95% CI, 71-87) for group A, 86% (95% CI, 77-91) for group B, 73% (95% CI, 64-81) for group C, and 73% (95% CI, 63-81) for group D (group B vs group A: HR, 0.69; 95% CI, 0.34-1.40; group C vs group A: HR, 1.25; 95% CI, 0.68-2.30; group D vs group B: HR, 2.05; 95% CI, 1.07-3.93).

RELATED: AIs Have Similar CVD Risk to Tamoxifen in Postmenopausal HR-positive Breast Cancer

Disease-free survival rates were 81% (95% CI, 72-88) for group A, 84% (95% CI, 72-91) for group B, 80% (95% CI, 70-86) for group C, and 75% (95% CI, 64-83) for group D. Researchers also found that patients who achieved total pathological complete response had longer progression-free survival compared with those who did not, suggesting that total pathological complete response could be an early indicator of long-term outcome.

In terms of safety, no new or long-term safety concerns were observed, and tolerability was similar across the 4 treatment arms.

Reference

  1. Gianni L, Pienkowski T, Im Y-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [published online ahead of print May 11, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)00163-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters